AC
CGTX icon

Apogem Capital’s Cognition Therapeutics CGTX Stock Holding History

Apogem Capital’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,667
Closed -$49K – 162
2022
Q1 		$49K Sell
17,667
-5,024
-22% -$19.4K 0.03% 171
2021
Q4 		$143K Buy
+22,691
New +$221K 0.09% 166

Other funds holding CGTX

PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Apogem Capital's CGTX Position: Q2 2022 in Review

Apogem Capital sold out of Cognition Therapeutics (CGTX) in Q2 2022, closing a stake of 17,667 shares — an estimated $49K sold.

Apogem Capital first reported a position in CGTX in Q4 2021 and held it in 2 quarters. The position peaked at $143K in Q4 2021. 28 funds tracked by Wall St. Rank hold CGTX as of Q2 2022.

  • Apogem Capital reported no remaining Cognition Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Apogem Capital sold 17,667 Cognition Therapeutics shares in Q2 2022, an estimated $49K.
  • Apogem Capital first reported a position in Cognition Therapeutics in Q4 2021 and held it in 2 quarters.
  • Apogem Capital's Cognition Therapeutics position peaked at $143K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2022.

Based on Apogem Capital's 13F filing for Q2 2022, filed 15 Aug 2022.